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Abstract The Japanese Society of Chemotherapy (JSC) 
conducted the ﬁ rst nationwide surveillance of bacterial 
respiratory pathogens during the period from January to 
August 2006. With the cooperation of 32 medical institu-
tions throughout Japan, a total of 924 strains belonging to 
seven clinically relevant bacterial species were collected 
from adult patients with well-diagnosed respiratory tract 
infections (RTIs). Antimicrobial susceptibility testing of the 
887 evaluable strains (205 Staphylococcus aureus, 200 Strep-
tococcus pneumoniae, 9 Streptococcus pyogenes, 165 Hae-
mophilus inﬂ uenzae, 91 Moraxella catarrhalis, 74 Klebsiella 
pneumoniae, and 143 Pseudomonas aeruginosa) to 42 anti-
bacterial agents was conducted at the Central Laboratory 
of the Research Center for Anti-infective Drugs of the Kita-
sato Institute, according to recommendations issued by the 
Clinical and Laboratory Standards Institute (CLSI). The 
antibacterial agents employed were 25 β-lactams, three ami-
noglycosides, four macrolides (including one azalide and 
one ketolide), one lincosamide, one tetracycline, two glyco-
peptides, ﬁ ve ﬂ uoroquinolones, and one oxazolidinone. The 
incidence of methicillin-resistant S. aureus (MRSA) was 
63.4%, and the incidences of penicillin-intermediately resis-
tant S. pneumoniae (PISP) and penicillin-resistant S. pneu-
moniae (PRSP) were 35.0% and 4.0%, respectively. Among 
H. inﬂ uenzae, 21.2% of the strains were found to be β-lac-
tamase-nonproducing ampicillin (ABPC)-intermediately 
resistant (BLNAI), 29.1% to be β-lactamase-nonproducing 
ABPC-resistant (BLNAR), and 4.8% to be β-lactamase-
producing ABPC-resistant (BLPAR) strains. The incidence 
of extended-spectrum β-lactamase-producing K. pneu-
moniae was 2.7% (2 of 74 strains). Three (2.1%) of the 143 
P. aeruginosa strains were found to be metallo-β-lactamase-
producing, including 1 (0.7%) multidrug-resistant strain. 
Through the nationwide surveillance, we obtained funda-
mental antimicrobial susceptibility data of clinically rele-
vant bacterial pathogens in adult RTI to various antibacterial 
agents. These data will be a useful reference for future 
periodic surveillance studies, as well as for investigations to 
control antimicrobial-resistant pathogens.
Key words Surveillance · Susceptibility · Drug · 
Resistance · Respiratory tract infection
Introduction
In order to investigate trends in the isolation of various 
bacterial pathogens and the emergence of antimicrobial 
resistance in these pathogens, the Japanese Society of Che-
motherapy (JSC) established a nationwide surveillance 
network in 2006. The ﬁ rst survey was conducted during the 
period from January to August 2006, with the cooperation 
of 32 medical institutions throughout Japan.
To keep the quality of surveillance high, the collection 
of bacterial strains was limited to clinically relevant species, 
i.e., Staphylococcus aureus, Streptococcus pneumoniae, 
Streptococcus pyogenes, Haemophilus inﬂ uenzae, Morax-
ella catarrhalis, Klebsiella pneumoniae, and Pseudomonas 
aeruginosa and to those isolated as causative bacteria from 
adult patients with well-diagnosed respiratory tract infec-
tions (RTIs). The incidence of these bacteria and their sus-
ceptibility to panels of antibacterial agents were analyzed 
according to stratiﬁ cations in various clinical settings.
Here we report, for the ﬁ rst time, the current bacterial 
species that cause RTI in adults and the trends in resistance 
to existing antibacterial agents, elucidated by the JSC-
conducted nationwide surveillance. These results obtained 
from this surveillance will be used as a set of controls for 
surveillance studies conducted in the future by the JSC and 
by other organizations as well.
Materials and methods
Strains and quality control
The causative bacteria of well-diagnosed adult RTI1 were 
isolated from sputum and from specimens of trans-tracheal 
aspiration or bronchoscopy, and their causality was con-
ﬁ rmed1 by quantitative culture, Gram staining, and observa-
tion of phagocytes, and/or by other means at the 32 medical 
institutions listed in Table 1. These bacteria were identiﬁ ed 
at the species level, suspended in the preservation broth 
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contained in Micro-bank tubes (Asuka Junyaku, Tokyo, 
Japan) at each institution, and sent to the Central Labora-
tory, the Research Center for Anti-infective Drugs, the 
Kitasato Institute (hereafter, the “Center”), in containers 
kept at −20°C. Uniform electronic data sheets for each 
patient from whom these strains were isolated were also 
completed at each institution and sent to the Center so that 
the microbiological data obtained could be stratiﬁ ed accord-
ing to the settings and proﬁ les of the patients and according 
to their diagnoses.
A total of 924 strains were received at the Center and 
they were kept at −80°C until the antimicrobial susceptibil-
ity testing was conducted. Re-identiﬁ cation and cultivation 
of the strains yielded 887 evaluable strains (205 S. aureus, 
200 S. pneumoniae, 9 S. pyogenes, 165 H. inﬂ uenzae, 91 M. 
catarrhalis, 74 K. pneumoniae, and 143 P. aeruginosa.
The accuracy of determination of the minimum inhibi-
tory concentrations (MICs) of antibacterial agents was con-
trolled according to the recommendations of the Clinical 
and Laboratory Standards Institute (CLSI), using the fol-
lowing control strains, respectively: S. aureus ATCC29213 
and Escherichia coli ATCC35218 for clinical isolates of S. 
aureus and M. catarrhalis; S. pneumoniae ATCC49619 for 
clinical isolates of S. pneumoniae and S. pyogenes; H. inﬂ u-
enzae ATCC49247 for clinical isolates of H. inﬂ uenzae; 
E. coli ATCC25922 for clinical isolates of K. pneumoniae 
and P. aeruginosa; and P. aeruginosa ATCC27853 for clini-
cal isolates of P. aeruginosa. E. coli ATCC35218 was used 
as a control strain in the determination of the MIC for β-
lactam antibiotics combined with β-lactamase inhibitors.2
Susceptibility testing and MIC determination
Antimicrobial susceptibility testing was performed accord-
ing to CLSI (formerly National Committee for Clinical 
Laboratory Standards [NCCLS]) standards M7-A72 for the 
micro-broth dilution method. In brief, cation-adjusted 
Mueller-Hinton broth (25 mg/l Ca2+ and 12.5 mg/l Mg2+; 
CA-MH broth) was used to measure MICs against S. aureus, 
M. catarrhalis, K. pneumoniae, and P. aeruginosa. For the 
determination of the MIC of oxacillin, NaCl was added at 
2% to CA-MH broth. For determining MICs against S. 
pneumoniae, S. pyogenes, and H. inﬂ uenzae, 15 μg/ml nico-
tinamide, 5 mg/ml yeast extract, and 5% horse blood were 
added to CA-MH broth.
A 0.005-ml portion of test organism solution, grown to 
turbidity of MacFarland number 0.5 and diluted tenfold 
with saline, was inoculated on the respective CA-MH broth 
to make a ﬁ nal volume of 0.1 ± 0.02 ml. The solution was 
poured into a microplate well where a serially diluted 
freeze-dried test agent was placed, and the MIC was deter-
mined with the MIC2000 system (Eiken Kagaku, Tokyo, 
Japan).
Antibacterial agents
Susceptibilities of the bacterial strains were tested for the 
following 42 antimicrobial agents: four penicillins, benzyl-
penicillin (PCG; Meiji Seika Kaisha, Tokyo, Japan), oxa-
cillin (MPIPC; Meiji), ampicillin (ABPC; Meiji), and 
piperacillin (PIPC; Taisyo-Toyama, Tokyo, Japan); three 
penicillins combined with β-lactamase inhibitors, clavulanic 
acid-amoxicillin (CVA/AMPC 1: 2; GlaxoSmithKline 
Beecham Pharmaceuticals, Middlesex, UK), sulbactam-
ABPC (SBT/ABPC 1: 2; Pﬁ zer Japan, Tokyo, Japan), and 
tazobactam-PIPC (TAZ/PIPC, TAZ ﬁ xed at 4 μg/ml and 
combined with various concentrations of PIPC; Taisyo-
Toyama); four oral cephems, cefaclor (CCL; Shionogi, 
Tokyo, Japan), cefdinir (CFDN; Astellas Pharma, Tokyo, 
Japan), cefcapene (CFPN; Shionogi), and cefditoren 
(CDTR; Meiji); eight parenteral cephems, cefazolin (CEZ; 
Astellas), cefoxitin (CFX; Banyu Pharmaceutical, Tokyo, 
Japan), cefmetazole (CMZ; Daiichi-Sankyo, Tokyo, Japan), 
cefotiam (CTM; Takeda Pharmaceutical, Tokyo, Japan), 
ceftazidime (CAZ; GlaxoSmithKline Beecham), ceftriax-
one (CTRX; Chugai Pharmaceutical, Tokyo, Japan), 
cefepime (CFPM; Meiji), and cefozopran (CZOP; Takeda); 
a monobactam, aztreonam (AZT; Eisai, Tokyo, Japan); ﬁ ve 
carbapenems, imipenem (IPM; Banyu), panipenem (PAPM; 
Daiichi-Sankyo), meropenem (MEPM; Dainippon Sumi-
tomo Pharma, Tokyo, Japan), biapenem (BIPM; Meiji), 
and doripenem (DRPM; Shionogi); three aminoglycosides, 
gentamicin (GM; Shionogi), amikacin (AMK; Banyu), and 
Table 1. Cooperating medical institutionsa
Ehime Prefectural Central Hospital, Matsuyama, Ehime
Faculty of Medicine University Hospital, Kagawa University, Kita, 
Kagawa
Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa
Fukushima Prefectural Aizu General Hospital, Aizuwakamatsu, 
Fukushima
Graduate School of Medical Sciences, Kyushu University, Fukuoka, 
Fukuoka
Hiroshima Prefectural Hospital, Hiroshima, Hiroshima
International Medical Center of Japan, Shinjuku, Tokyo
Iwate Prefectural Central Hospital, Morioka, Iwate
Japanese Red Cross Sendai Hospital, Sendai, Miyagi
Kawasaki Medical School Hospital, Kurashiki, Okayama
Kurume University School of Medicine, Kurume, Fukuoka
Kyorin University Hospital, Mitaka, Tokyo
Matsue Red Cross Hospital, Matsue, Shimane
Nagasaki University School of Medicine, Nagasaki, Nagasaki
National Hospital Organization Tokyo Medical Center, Meguro, 
Tokyo
Niigata City General Hospital, Niigata, Niigata
Niigata University Medical & Dental Hospital, Niigata, Niigata
Oita University Faculty of Medicine, Yufu, Oita
Saga Medical School Faculty of Medicine, Saga University, Saga, 
Saga
St. Luke’s International Hospital, Chuo, Tokyo
Saiseikai Kumamoto Hospital, Kumamoto, Kumamoto
Saka General Hospital, Shiogama, Miyagi
Sanyudo Hospital, Yonezawa, Yamagata
Sendai Kousei Hospital, Sendai, Miyagi
Shimonoseki City Hospital, Shimonoseki, Yamaguchi
Shinrakuen Hospital, Niigata, Niigata
South Miyagi Medical Center, Ogawara, Miyagi
Tokyo Metropolitan Toshima Hospital, Toshima, Tokyo
Tottori University Hospital, Yonago, Tottori
Toyama Prefectural Central Hospital, Toyama, Toyama
Yamagata Saisei Hospital, Yamagata, Yamagata
Yamanashi Red Cross Hospital, Fujikawaguchiko, Yamanashi
a Listed in alphabetical order; locations by city and prefecture
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arbekacin (ABK; Meiji); four macrolides, erythromycin 
(EM; Dainippon Sumitomo), clarithromycin (CAM; Taisyo-
Toyama), azithromycin (AZM; Pﬁ zer), and telithromycin 
(TEL; Sanoﬁ -Aventis, Milan, Italy); a lincosamide, clinda-
mycin (CLDM; Dainippon Sumitomo.); a tetracycline, 
minocycline (MINO; Wyeth Pharmaceuticals, Pennsylva-
nia, PA, USA/Takeda); two glycopeptides, vancomycin 
(VCM; Shionogi) and teicoplanin (TEIC; Astellas.); ﬁ ve 
ﬂ uoroquinolones, ciproﬂ oxacin (CPFX; BayerYakuhin, 
Tokyo, Japan), levoﬂ oxacin (LVFX; Daiichi-Sankyo), tosu-
ﬂ oxacin (TFLX; Taisyo-Toyama), gatiﬂ oxacin (GFLX; 
Kyorin Pharmaceutical, Tokyo, Japan), and pazuﬂ oxacin 
(PZFX; Taisyo-Toyama); and an oxazolidinone, linezolid 
(LZD; Pﬁ zer). These antimicrobial agents were serially 
diluted and placed in a freeze-dried state in the respective 
wells of microplates. The stability of the antimicrobial agent-
containing microplates was guaranteed by the manufacturer 
(Eiken Kagaku) for 9 months.
Detection of β-lactamases
To detect β-lactamases in H. inﬂ uenzae, tests with Nitroce-
ﬁ n disks (Kanto Chemical, Tokyo, Japan) were conducted 
according to the reference manual supplied by the 
manufacturer.
A recently established rapid detection method, Cica-
Beta Test 1 (Kanto Chemical), designed to detect extended-
spectrum β-lactamase (ESBL) and metallo-β-lactamase 
(MBL) directly in colonies of Gram-negative rods,3,4 was 
employed to identify K. pneumoniae and P. aeruginosa 
strains which produce such β-lactamases.
Results
Antimicrobial susceptibility of S. aureus
S. aureus was the largest species in number (205/887; 23.1%) 
among the evaluable strains in this investigation. The anti-
microbial susceptibility of these S. aureus strains to 41 anti-
bacterial agents was tested. One hundred and thirty strains 
(63.4%) were found to be methicillin-resistant S. aureus 
(MRSA; MIC of MPIPC ≥4 μg/ml; Table 2).
Antimicrobial susceptibility of methicillin-susceptible S. 
aureus (MSSA)
The MIC90s of penicillins against the 75 MSSA strains were 
16–32 μg/ml; however, the MIC90s of penicillins in combina-
tions with β-lactamase inhibitors (CVA/AMPC, SBT/
ABPC, and TAZ/PIPC) were decreased, at 2.0 μg/ml. The 
MIC90s of CCL, CAZ, CTRX, CFPM, CFX, and CMZ 
ranged from 2.0 to 8.0 μg/ml, and those of the other six 
cephems ranged from 0.5 to 1.0 μg/ml. The carbapenems 
showed the strongest activity, with MIC90s of ≤0.125 μg/ml. 
As for the aminoglycosides, GM, AMK, and ABK showed 
MIC90 values of 32, 8.0, and 1.0 μg/ml, respectively. Among 
the macrolide-lincosamide antibiotics, TEL and CLDM 
showed relatively strong activity, with MIC90 values of 0.25 
and 0.5 μg/ml, respectively, but the rest of the macrolides 
showed weak activity, with MIC90 values of ≥128 μg/ml. 
Relatively strong activities of MINO, VCM, TEIC, and 
all ﬁ ve ﬂ uoroquinolones were noted, with MIC90s of 
0.125–1.0 μg/ml.
Antimicrobial susceptibility of MRSA
Only 4 of the 41 antibacterial agents tested, ABK, VCM, 
TEIC, and LZD, showed appreciable activity against 
MRSA, with MIC90 values of 2.0, 1.0, 2.0, and 4.0 μg/ml, 
respectively. The other 37 agents showed weak or almost 
no activity, with MIC90 values of 16- ≥256 μg/ml against 
these MRSA strains.
Antimicrobial susceptibility of S. pneumoniae
The antimicrobial susceptibilities of the 200 strains of S. 
pneumoniae to 39 antimicrobial agents were determined, 
and 122 (61.0%) of the strains were identiﬁ ed as penicillin-
susceptible (PSSP), 70 (35.0%) as penicillin-intermediately 
resistant (PISP), and 8 (4.0%) as penicillin-resistant strains 
(PRSP) according to the breakpoint for PCG deﬁ ned by the 
CLSI standards.2
Two cephems, CFPN and CDTR, all ﬁ ve carbapenems, 
both glycopeptides, TEL, and two ﬂ uoroquinolones, TFLX 
and GFLX, showed strong activities (MIC90 ≤0.5 μg/ml) 
against these S. pneumoniae strains regardless of their dif-
ferent susceptibilities to PCG. On the other hand, the ami-
noglycosides were substantially less active, as expected, 
to S. pneumoniae, with MIC50 values of 8.0–64 μg/ml 
(Table 3).
Antimicrobial susceptibility of PSSP
Among the β-lactams, CCL and CAZ showed high MIC90 
values (2.0 and 4.0 μg/ml, respectively), while the MIC90s of 
the other β-lactams were ≤0.5 μg/ml. Particularly, TAZ/
PIPC and all the carbapenems showed markedly strong 
activities, with MIC90s of ≤0.06 μg/ml. With regard to the 
ﬂ uoroquinolones, CPFX, LVFX, and PZFX showed mod-
erate activities (MIC50 of 2.0 μg/ml), while TFLX and GFLX 
were very active.
Antimicrobial susceptibility of PISP
The antimicrobial activities of the penicillins, including the 
combinations with β-lactamase inhibitors, were relatively 
weak against PISP, with MIC90s of 1.0 or 2.0 μg/ml. Among 
the oral cephems, CFPN and CDTR showed relatively 
strong activities, with MIC90s of 0.5 μg/ml, while CCL and 
CFDN were less active, with MIC90s of 32 and 4.0 μg/ml, 
respectively. The antimicrobial activities of the parenteral 
cephems were found to be moderate to relatively weak, 
with MIC90s ranging from 1.0 to 8.0 μg/ml. The MIC90s of 
four carbapenems, IPM, MEPM, BIPM, and DRPM, were 
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low, at 0.25 μg/ml, and PAPM showed especially strong 
activity, with an MIC90 of ≤0.06 μg/ml.
With regard to the ﬂ uoroquinolones, the MIC90 values of 
TFLX and GFLX were 0.25 and 0.5 μg/ml, respectively, 
while those of CPFX, LVFX, and PZFX were 1.0, 1.0, and 
2.0 μg/ml, respectively. The activities of the macrolide-
lincosamide antibiotics against PISP were found to be very 
weak (MIC90s of ≥128 μg/ml), except that TEL showed 
strong activity (MIC90 of 0.25 μg/ml).
Antimicrobial susceptibility of PRSP
Although the number of PRSP strains was small (eight 
strains), some tendencies in antimicrobial susceptibility 
were noted. These strains were highly susceptible to IPM, 
PAPM, TEL, VCM, TEIC, TFLX, and GFLX (MIC90 
values of 0.125–0.5 μg/ml), but they were relatively less sus-
ceptible to CEZ, CTM, CAZ, CMZ, and MINO.
Antimicrobial susceptibility of H. inﬂ uenzae
The antimicrobial susceptibilities of the 165 H. inﬂ uenzae 
strains against 37 antibacterial agents were determined. 
According to the CLSI breakpoint for ABPC,2 74 strains 
(44.8%) were found to be ABPC-susceptible, 35 (21.2%) to 
be ABPC-intermediately resistant, and 56 (33.9%) to be 
ABPC-resistant strains. With the use of Nitroceﬁ n disks 
(Kanto Chemical), all ABPC-intermediately resistant and 
Table 2. Susceptibility of Staphylococcus aureus
Antibacterial 
agents
Staphylococcus aureus (n = 205) MSSA (MPIPC  2 μg/ml) (n = 75) MRSA (MPIPC  4 μg/ml) 
(n = 130)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
PCG 16 64 0.06–128 2 16 0.06–64 16 64 2–128
MPIPC 64 256 0.06–256 0.25 0.5 0.06–2 128 256 4–256
ABPC 16 64 0.125–128 2 16 0.125–64 32 64 4–128
SBT/ABPC 16 32 0.125–64 1 2 0.125–16 16 32 2–64
CVA/AMPC 16 32 0.125–128 1 2 0.125–4 16 32 2–128
PIPC 64 256 0.5–256 4 32 0.5–128 128 256 8–256
TAZ/PIPC 64 256 0.5–256 1 2 0.5–16 128 256 2–256
CCL 128 256 0.5–256 2 4 0.5–16 128 256 8–256
CFDN 128 128 0.125–128 0.25 0.5 0.125–4 128 128 1–128
CFPN 256 256 0.5–256 1 1 0.5–8 256 256 4–256
CDTR 64 128 0.25–128 0.5 1 0.25–8 64 128 2–128
CEZ 128 256 0.25–256 0.5 1 0.25–2 128 256 2–256
CTM 64 256 0.5–256 1 1 0.5–4 128 256 2–256
CFX 256 256 2–256 4 4 2–32 256 256 4–256
CMZ 16 64 1–128 1 2 1–8 32 64 2–128
CAZ 128 128 2–128 8 8 2–64 128 128 8–128
CTRX 256 256 1–256 4 4 1–32 256 256 4–256
CFPM 64 256 2–256 2 4 2–8 128 256 4–256
CZOP 16 32 0.5–128 1 1 0.5–1 32 64 0.5–128
IPM 8 64 0.06–128 0.06 0.06 0.06–0.5 16 64 0.06–128
PAPM 8 32 0.06–64 0.06 0.06 0.06–0.25 16 32 0.06–64
MEPM 8 32 0.06–64 0.06 0.125 0.06–1 16 32 0.125–64
BIPM 8 32 0.06–128 0.06 0.06 0.06–0.25 16 64 0.125–128
DRPM 4 16 0.06–32 0.06 0.06 0.06–0.5 8 16 0.125–32
GM 0.5 128 0.125–256 0.25 32 0.125–256 32 128 0.25–256
AMK 8 32 1–256 2 8 1–64 16 32 1–256
ABK 0.5 1 0.25–8 0.5 1 0.25–4 0.5 2 0.25–8
EM 256 256 0.25–256 0.5 256 0.25–256 256 256 0.5–256
CAM 128 128 0.125–128 0.25 128 0.125–128 128 128 1–128
AZM 128 128 0.25–128 0.5 128 0.25–128 128 128 0.5–128
TEL 64 64 0.06–64 0.125 0.25 0.06–64 64 64 0.06–64
CLDM 256 256 0.125–256 0.25 0.5 0.125–256 256 256 0.25–256
MINO 0.25 16 0.06–32 0.125 0.25 0.06–0.5 8 16 0.06–32
VCM 1 1 0.5–2 1 1 0.5–2 1 1 0.5–2
TEIC 1 1 0.25–8 0.5 1 0.25–2 1 2 0.25–8
CPFX 16 256 0.06–256 0.25 1 0.06–64 128 256 0.125–256
LVFX 8 256 0.06–256 0.25 0.5 0.06–16 32 256 0.125–256
TFLX 8 32 0.06–32 0.06 0.25 0.06–32 32 32 0.06–32
GFLX 2 64 0.06–256 0.06 0.125 0.06–4 4 64 0.06–256
PZFX 4 256 0.125–256 0.25 0.25 0.125–16 8 256 0.125–256
LZD 2 4 1–4 2 4 2–4 2 4 1–4
SBT: ABPC = 1 : 2 (ﬁ xed ratio)
CVA: AMPC = 1 : 2 (ﬁ xed ratio)
TAZ/PIPC TAZ ﬁ xed at 4 μg/ml and combined with various concentrations of PIPC
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Table 3. Susceptibility of Streptococcus pneumoniae
Antibacterial 
agents
Streptococcus pneumoniae (n = 200) PSSP (PCG  0.06 μg/ml) (n = 122) PISP (0.125 μg/ml  PCG 1 μg/ml) 
(n = 70)
PRSP (PCG  2 μg/ml) (n = 8)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
PCG 0.06 1 0.06–2 0.06 0.06 0.06–0.06 0.5 1 0.125–1 2 2 2–2
ABPC 0.125 2 0.06–8 0.06 0.25 0.06–1 1 2 0.25–4 4 8 2–8
SBT/ABPC 0.125 2 0.06–8 0.06 0.125 0.06–0.25 1 2 0.25–8 4 4 2–4
CVA/AMPC 0.06 1 0.06–4 0.06 0.125 0.06–0.5 0.5 1 0.125–2 1 4 1–4
PIPC 0.06 2 0.06–4 0.06 0.125 0.06–0.5 1 2 0.125–2 2 4 2–4
TAZ/PIPC 0.06 2 0.06–8 0.06 0.06 0.06–1 1 2 0.06–8 2 4 2–4
CCL 1 32 0.06–128 0.5 2 0.06–4 16 32 0.5–64 64 128 32–128
CFDN 0.25 4 0.06–8 0.125 0.5 0.06–1 2 4 0.125–4 4 8 4–8
CFPN 0.25 0.5 0.06–2 0.125 0.5 0.06–1 0.5 0.5 0.06–1 0.5 2 0.5–2
CDTR 0.125 0.25 0.06–1 0.06 0.125 0.06–0.5 0.25 0.5 0.06–0.5 0.5 1 0.25–1
CEZ 0.25 2 0.06–4 0.125 0.25 0.06–1 2 2 0.25–4 4 4 2–4
CTM 0.25 2 0.06–8 0.125 0.5 0.06–2 1 4 0.125–8 4 8 2–8
CMZ 0.5 4 0.06–8 0.25 0.5 0.06–2 1 8 0.25–8 4 8 1–8
CAZ 2 8 0.06–16 2 4 0.06–16 4 8 0.5–16 8 16 8–16
CTRX 0.25 1 0.06–2 0.125 0.5 0.06–2 0.5 1 0.125–1 1 2 1–2
CFPM 0.5 1 0.06–1 0.125 0.5 0.06–1 0.5 1 0.125–1 1 1 0.5–1
CZOP 0.25 1 0.06–2 0.125 0.5 0.06–2 0.5 1 0.06–1 1 2 0.5–2
IPM 0.06 0.125 0.06–0.5 0.06 0.06 0.06–0.125 0.06 0.25 0.06–0.5 0.25 0.5 0.06–0.5
PAPM 0.06 0.06 0.06–0.125 0.06 0.06 0.06–0.06 0.06 0.06 0.06–0.125 0.06 0.125 0.06–0.125
MEPM 0.06 0.25 0.06–1 0.06 0.06 0.06–0.125 0.125 0.25 0.06–0.5 0.25 1 0.25–1
BIPM 0.06 0.25 0.06–1 0.06 0.06 0.06–0.06 0.125 0.25 0.06–0.5 0.25 1 0.125–1
DRPM 0.06 0.25 0.06–1 0.06 0.06 0.06–0.06 0.125 0.25 0.06–0.5 0.25 1 0.125–1
GM 8 8 0.5–32 8 8 0.5–32 8 16 2–16 8 8 4–8
AMK 64 128 0.5–128 64 128 0.5–128 64 128 8–128 64 64 32–64
ABK 16 32 0.25–64 16 32 0.25–64 32 32 2–64 16 64 2–64
EM 2 256 0.06–256 2 256 0.06–256 2 256 0.06–
256
2 256 0.25–256
CAM 2 128 0.06–128 2 128 0.06–128 2 128 0.06–
128
2 128 0.06–128
AZM 4 128 0.06–128 4 128 0.06–128 2 128 0.06–
128
2 128 0.06–128
TEL 0.06 0.25 0.06–1 0.06 0.125 0.06–1 0.06 0.25 0.06–0.5 0.125 0.5 0.06–0.5
CLDM 0.125 256 0.06–256 0.125 256 0.06–256 0.125 256 0.06–
256
0.25 256 0.06–256
MINO 2 8 0.06–16 2 8 0.06–16 2 8 0.06–16 4 16 0.125–16
VCM 0.25 0.5 0.25–1 0.25 0.5 0.25–1 0.25 0.25 0.25–0.5 0.25 0.5 0.25–0.5
TEIC 0.06 0.125 0.06–0.25 0.06 0.125 0.06–0.25 0.06 0.125 0.06–0.25 0.06 0.125 0.06–0.125
CPFX 1 2 0.06–32 1 2 0.06–16 1 1 0.25–32 1 2 0.5–2
LVFX 1 2 0.06–8 1 2 0.06–8 1 1 0.5–8 1 2 1–2
TFLX 0.125 0.25 0.06–8 0.125 0.25 0.06–4 0.125 0.25 0.06–8 0.125 0.25 0.125–0.25
GFLX 0.25 0.5 0.06–4 0.25 0.25 0.06–4 0.25 0.5 0.06–2 0.25 0.5 0.125–0.5
PZFX 2 2 0.5–32 2 2 0.5–32 2 2 1–16 2 2 1–2
LZD 0.5 1 0.25–2 0.5 1 0.25–2 0.5 1 0.25–1 1 1 0.25–1
SBT: ABPC = 1 : 2 (ﬁ xed ratio)
CVA: AMPC = 1 : 2 (ﬁ xed ratio)
TAZ/PIPC, TAZ ﬁ xed at 4 μg/ml and combined with various concentrations of PIPC
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48 (85.7%) of the ABPC-resistant strains were found to 
be β-lactamase-nonproducing. They were deﬁ ned as β-
lactamase-nonproducing ABPC-intermediate H. inﬂ uenzae 
(BLNAI) and β-lactamase-nonproducing ABPC-resistant 
H. inﬂ uenzae (BLNAR), respectively. The other 8 ABPC-
resistant strains were found to be β-lactamase-producing 
and were designated as β-lactamase-producing ABPC-
resistant H. inﬂ uenzae (BLPAR).
Regardless of their susceptibility to ABPC, all of the H. 
inﬂ uenzae strains, except for BLPAR, were extremely sus-
ceptible to all ﬁ ve ﬂ uoroquinolones (MIC90s ≤0.06 μg/ml 
(Table 4).
Antimicrobial susceptibility of ABPC-susceptible strains
Of the 32 antibacterial agents other than ﬂ uoroquinolones 
tested, 7 agents (PIPC, TAZ/PIPC, CDTR, CAZ, CTRX, 
MEPM, and MINO) showed strong activities, with MIC90s 
of ≤0.5 μg/ml.
Antimicrobial susceptibility of BLNAI and 
BLNAR strains
The BLNAI and BLNAR strains were found to be substan-
tially susceptible (MIC90 ≤0.5 μg/ml) to PIPC, TAZ/PIPC, 
CDTR, CTRX, MEPM, and MINO. Of the cephems, CCL, 
CEZ, CTM, CZOP, and CMZ had low activity or were not 
active against BLNAI and BLNAR, showing MIC90s of 64 
and 128; 64 and ≥256; 64 and 64; 8 and 32; and 8 and 16 μg/
ml, respectively.
Antimicrobial susceptibility of BLPAR strains
Although the number of BLPAR strains was small (eight 
strains), some tendencies in antimicrobial susceptibility 
were noted. The β-lactamase inhibitors markedly restored 
the activities of penicillins against these strains: SBT 
decreased the MIC90 of ABPC from ≥256 to 8.0 μg/ml, and 
TAZ decreased the MIC90 of PIPC from ≥256 to as low as 
0.5 μg/ml. Of the cephems, CDTR and CTRX showed 
appreciable activity, with MIC90s of 0.25 and 0.5 μg/ml, 
respectively.
Antimicrobial susceptibility of M. catarrhalis
The susceptibility of the 91 M. catarrhalis strains to 37 anti-
bacterial agents was tested. β-Lactamase inhibitors restored 
the activities of penicillins against these strains: SBT 
decreased the MIC90 of ABPC from 16 to 0.25 μg/ml, and 
TAZ decreased the MIC90 of PIPC from 8.0 to ≤0.06 μg/ml. 
Although AMPC was not included in the panel, CVA was 
thought to restore the activity of AMPC, because the MIC90 
of CVA/AMPC was very low (0.25 μg/ml). Four of the ﬁ ve 
carbapenems (PAPM, MEPM, BIPM, and DRPM), AZM, 
and all ﬁ ve ﬂ uoroquinolones showed very strong activities, 
with MIC90s of ≤0.06 μg/ml. The activities of IPM, MINO, 
CAM, and TEL were also strong, with MIC90s of 0.125 μg/
ml. Several cephems (CFDN, CFPN, CDTR, CAZ, and 
CMZ), two aminoglycosides (GM and ABK), and EM 
showed MIC90s of 0.25–0.5 μg/ml (Table 5).
Antimicrobial susceptibility of K. pneumoniae
The susceptibility of the 74 K. pneumoniae strains to 32 
antibacterial agents was determined. The agents that showed 
very strong activity (MIC90s ≤0.06 μg/ml) were CFPM, AZT, 
MEPM, and DRPM. Two oral cephems, CFDN and CDTR; 
four parenteral cephems, CTM, CAZ, CTRX, and CZOP; 
three carbapenems, IPM, PAPM, and BIPM; two aminogly-
cosides, GM and ABK; and all ﬁ ve ﬂ uoroquinolones showed 
relatively strong activities, with MIC90s of 0.125–0.5 μg/ml 
(Table 6).
Antimicrobial susceptibility of P. aeruginosa
The antibacterial activities of 21 agents were measured 
against the 143 P. aeruginosa strains. All three aminoglyco-
sides and one of the ﬁ ve ﬂ uoroquinolones, CPFX, showed 
moderate activities, with MIC90s of 4.0 μg/ml. Two paren-
teral cephems, CFPM and CZOP; three carbapenems, 
MEPM, BIPM, and DRPM; and one ﬂ uoroquinolone, 
PZFX, showed MIC90s of 8.0 μg/ml. The MIC90s of CAZ, 
AZT, IPM, LVFX, and GFLX were 16 μg/ml, while those 
of the remaining agents tested were 32- ≥256 μg/ml (Table 
7). Only one strain was identiﬁ ed as multidrug-resistant P. 
aeruginosa (MDRP) from its proﬁ le of antimicrobial resis-
tance to IPM, AMK, and CPFX.
Cica-beta test 1 ﬁ ndings in K. pneumoniae and 
P. aeruginosa
Two of the 74 K. pneumoniae strains, were suspected to be 
ESBL-producing strains, detected by the Cica-beta test 1 
(Kanto Chemical). One of the 143 P. aeruginosa strains was 
suspected to be an AmpC-high-producing strain, and three 
were suspected to be MBL-producing strains, as detected 
by the test.
Discussion
Although so many antibacterial agents, particularly β-
lactam antibiotics and ﬂ uoroquinolones, have been invented 
and developed in Japan, there is no accessible public data-
base showing the susceptibility of bacterial pathogens to 
contemporaneously used antibacterial agents in Japan. In 
order to grasp the trends in the isolation of various bacterial 
pathogens and the emergence of antimicrobial resistance in 
these pathogens, the JSC established a nationwide surveil-
lance network in 2006 so that the data obtained through the 
surveillance would enable the JSC to construct such a 
database.
Before the ﬁ rst survey was initiated, the JSC Sur-
veillance Committee was formed, and the Committee 
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Table 4. Susceptibility of Haemophilus inﬂ uenzae
Antibacterial 
agents
Haemophilus inﬂ uenzae (n = 165) BLNAI (ABPC = 2 μg/ml; 
β-Lactamase (−) (n = 35)
BLNAR (ABPC  4 μg/ml; 
β-Lactamase (−) (n = 48)
BLPAR (ABPC  4 μg/ml; β-Lactamase 
(+) (n = 8)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
MIC range 
(μg/ml)
PCG 4 8 0.06–256 4 8 2–16 8 16 4–32 256 256 32–256
ABPC 2 8 0.125–256 2 2 2–2 4 8 4–16 256 256 16–256
SBT/ABPC 2 4 0.125–16 2 4 1–4 4 8 4–16 4 8 1–8
CVA/AMPC 2 8 0.25–16 2 4 1–8 8 8 2–16 2 8 1–8
PIPC 0.06 0.25 0.06–256 0.06 0.25 0.06–0.25 0.06 0.5 0.06–64 64 256 32–256
TAZ/PIPC 0.06 0.125 0.06–128 0.06 0.25 0.06–0.25 0.06 0.5 0.06–128 0.06 0.5 0.06–0.5
CCL 8 64 0.125–256 32 64 2–128 32 128 8–128 32 256 2–256
CFDN 2 8 0.06–16 4 8 0.5–16 8 8 0.5–16 2 8 0.5–8
CFPN 0.5 2 0.06–4 1 4 0.125–4 2 4 0.06–4 0.125 4 0.06–4
CDTR 0.06 0.25 0.06–1 0.125 0.25 0.06–0.5 0.25 0.25 0.06–0.5 0.06 0.25 0.06–0.25
CEZ 8 128 0.25–256 16 64 1–128 64 256 2–256 32 256 2–256
CTM 8 64 0.125–64 16 64 0.125–64 32 64 1–64 8 64 2–64
CMZ 4 8 0.125–32 8 8 4–32 8 16 2–32 4 8 2–8
CAZ 0.25 0.5 0.06–8 0.5 1 0.06–4 0.5 2 0.125–8 0.25 2 0.06–2
CTRX 0.125 0.5 0.06–1 0.25 0.5 0.06–0.5 0.25 0.5 0.06–1 0.06 0.5 0.06–0.5
CFPM 1 2 0.06–32 1 2 0.25–4 2 4 0.5–32 0.25 2 0.125–2
CZOP 4 16 0.06–64 8 8 1–16 8 32 2–64 0.5 16 0.25–16
AZT 0.5 2 0.06–16 0.5 2 0.06–16 1 4 0.06–8 0.125 4 0.06–4
IPM 0.5 4 0.06–32 1 4 0.25–8 1 4 0.06–16 2 8 0.125–8
PAPM 0.5 2 0.06–16 1 4 0.25–4 1 4 0.06–8 2 4 0.125–4
MEPM 0.125 0.5 0.06–2 0.125 0.25 0.06–0.5 0.25 0.5 0.06–2 0.06 1 0.06–1
BIPM 2 8 0.06–32 2 8 0.5–8 4 8 0.06–16 2 8 0.25–8
DRPM 0.25 1 0.06–4 0.25 1 0.06–2 0.5 2 0.06–4 0.25 2 0.06–2
GM 1 1 0.125–4 1 1 0.25–2 1 1 0.25–2 1 1 0.5–1
AMK 4 8 0.25–8 4 8 1–8 4 4 1–8 2 8 2–8
ABK 2 4 0.25–8 2 4 1–4 2 4 0.5–4 2 4 1–4
EM 4 4 0.5–16 4 8 2–16 4 4 2–8 4 16 2–16
CAM 8 8 0.25–32 8 16 2–32 4 8 2–32 8 32 1–32
AZM 0.5 1 0.06–2 0.5 1 0.125–2 0.5 1 0.125–2 0.5 2 0.25–2
TEL 1 2 0.06–8 1 4 0.5–8 1 2 0.5–4 1 2 0.06–2
CLDM 8 16 0.06–64 8 16 2–32 4 16 2–64 8 16 0.25–16
MINO 0.25 0.5 0.06–2 0.25 0.5 0.06–0.5 0.25 0.5 0.06–1 0.25 1 0.125–1
CPFX 0.06 0.06 0.06–8 0.06 0.06 0.06–0.06 0.06 0.06 0.06–0.06 0.06 8 0.06–8
LVFX 0.06 0.06 0.06–4 0.06 0.06 0.06–0.06 0.06 0.06 0.06–0.125 0.06 4 0.06–4
TFLX 0.06 0.06 0.06–32 0.06 0.06 0.06–0.06 0.06 0.06 0.06–0.06 0.06 32 0.06–32
GFLX 0.06 0.06 0.06–2 0.06 0.06 0.06–0.06 0.06 0.06 0.06–0.06 0.06 2 0.06–2
PZFX 0.06 0.06 0.06–4 0.06 0.06 0.06–0.06 0.06 0.06 0.06–0.06 0.06 4 0.06–4
SBT: ABPC = 1 : 2 (ﬁ xed ratio)
CVA: AMPC = 1 : 2 (ﬁ xed ratio)
TAZ/PIPC, TAZ ﬁ xed at 4 μg/ml and combined with various concentrations of PIPC
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established several rules to avoid confounding data caused 
by nonpathogenic bacteria: the collection of samples was 
limited to relevant bacterial species isolated from clean 
specimens obtained from patients with well-diagnosed 
infectious diseases.
The ﬁ rst surveillance was conducted during the period 
from January to August 2006; the scope of the survey 
was limited to respiratory tract infections (RTIs) in 
adults. These strict rules were adhered to, and a total of 952 
strains were collected at 32 institutions throughout Japan; 
887 strains (93.2%) were found to be evaluable (via re-
identiﬁ cation and cultivation at the Central Laboratory) for 
the determination of their susceptibilities to antibacterial 
agents.
To avoid commercial bias, the Committee requested 
opinions from the public on the selection of antibacterial 
agents to be subjected to this surveillance, and 42 agents of 
various classes were employed. Among these, several stan-
dard agents, such as benzylpenicillin (PCG), ampicillin 
(ABPC), cefazolin (CEZ), gentamicin (GM), clindamycin 
(CLDM), minocycline (MINO), and others were included 
for the purpose of comparing the data obtained from this 
surveillance with those published in the past.
The uniform electronic data sheets supplied to the 32 
institutions from the Central Laboratory, along with the 
Micro-bank tubes (Asuka Junyaku) ﬁ lled with the preserva-
tion broth, enabled the Committee to stratify the clinical 
isolates according to diagnoses, patients’ backgrounds, 
and the clinical settings of the patients from whom these 
pathogens were isolated. Analyses of these pathogens 
according to these stratiﬁ cation categories will be published 
elsewhere.
Of the 887 evaluable strains in the present study, S. 
aureus was the largest in number (205 strains), followed by 
S. pneumoniae (200), H. inﬂ uenzae (165), P. aeruginosa 
(143), M. catarrhalis (91), and K. pneumoniae (74) in this 
order; only 9 S. pyogenes strains were included. Conse-
quently, the susceptibilities of S. aureus strains to 41 agents, 
those of S. pneumoniae to 39 agents, those of H. inﬂ uenzae 
and M. catarrhalis to 37 agents, those of K. pneumoniae to 
32 agents, and those of P. aeruginosa to 21 agents were 
investigated.
Table 5. Susceptibility of Moraxella catarrhalis (n = 91)
Antibacterial agents MIC50 (μg/ml) MIC90 (μg/ml) MIC range (μg/ml)
PCG 8 16 0.06–32
ABPC 4 16 0.06–32
SBT/ABPC 0.125 0.25 0.06–0.25
CVA/AMPC 0.25 0.25 0.06–0.5
PIPC 2 8 0.06–16
TAZ/PIPC 0.06 0.06 0.06–0.06
CCL 1 4 0.25–16
CFDN 0.25 0.25 0.06–0.5
CFPN 0.25 0.5 0.06–1
CDTR 0.25 0.5 0.06–1
CEZ 4 8 0.5–16
CTM 1 2 0.25–2
CMZ 0.25 0.5 0.06–1
CAZ 0.06 0.25 0.06–1
CTRX 0.5 1 0.06–2
CFPM 0.5 2 0.125–4
CZOP 1 2 0.25–4
AZT 1 2 0.125–4
IPM 0.06 0.125 0.06–0.25
PAPM 0.06 0.06 0.06–0.06
MEPM 0.06 0.06 0.06–0.06
BIPM 0.06 0.06 0.06–0.125
DRPM 0.06 0.06 0.06–0.06
GM 0.125 0.25 0.06–0.25
AMK 0.5 1 0.125–1
ABK 0.25 0.5 0.06–1
EM 0.125 0.5 0.06–32
CAM 0.06 0.125 0.06–32
AZM 0.06 0.06 0.06–64
TEL 0.06 0.125 0.06–64
CLDM 1 4 0.5–256
MINO 0.06 0.125 0.06–0.5
CPFX 0.06 0.06 0.06–0.5
LVFX 0.06 0.06 0.06–2
TFLX 0.06 0.06 0.06–0.125
GFLX 0.06 0.06 0.06–0.5
PZFX 0.06 0.06 0.06–1
SBT: ABPC = 1 : 2 (ﬁ xed ratio)
CVA: AMPC = 1 : 2 (ﬁ xed ratio)
TAZ/PIPC, TAZ ﬁ xed at 4 μg/ml and combined with various concentrations of PIPC
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Table 6. Susceptibility of Klebsiella pneumoniae (n = 74)
Antibacterial agents MIC50 (μg/ml) MIC90 (μg/ml) MIC range (μg/ml)
ABPC 64 128 4–256
SBT/ABPC 4 8 2–128
CVA/AMPC 2 4 1–32
PIPC 8 16 2–256
TAZ/PIPC 2 4 0.5–64
CCL 0.5 1 0.25–256
CFDN 0.125 0.25 0.06–128
CFPN 0.5 1 0.125–64
CDTR 0.25 0.5 0.06–128
CEZ 1 2 1–256
CTM 0.125 0.5 0.06–256
CMZ 1 1 0.5–256
CAZ 0.125 0.25 0.06–64
CTRX 0.06 0.125 0.06–256
CFPM 0.06 0.06 0.06–32
CZOP 0.06 0.125 0.06–256
AZT 0.06 0.06 0.06–8
IPM 0.25 0.5 0.06–4
PAPM 0.125 0.25 0.06–4
MEPM 0.06 0.06 0.06–4
BIPM 0.125 0.5 0.06–1
DRPM 0.06 0.06 0.06–4
GM 0.25 0.5 0.125–0.5
AMK 1 1 0.25–2
ABK 0.5 0.5 0.25–1
AZM 4 4 1–8
MINO 2 4 0.5–128
CPFX 0.06 0.25 0.06–1
LVFX 0.06 0.5 0.06–1
TFLX 0.06 0.25 0.06–0.5
GFLX 0.06 0.5 0.06–2
PZFX 0.06 0.25 0.06–1
SBT: ABPC = 1 : 2 (ﬁ xed ratio)
CVA: AMPC = 1 : 2 (ﬁ xed ratio)
TAZ/PIPC, TAZ ﬁ xed at 4 μg/ml and combined with various concentrations of PIPC
Table 7. Susceptibility of Pseudomonas aeruginosa (n = 143)
Antibacterial agents MIC50 (μg/ml) MIC90 (μg/ml) MIC range (μg/ml)
PIPC 4 128 0.25–256
TAZ/PIPC 4 128 0.06–256
CAZ 2 16 0.06–128
CTRX 32 256 1–256
CFPM 2 8 0.125–256
CZOP 1 8 0.125–256
AZT 4 16 0.06–256
IPM 2 16 0.06–128
PAPM 4 32 0.125–256
MEPM 1 8 0.06–256
BIPM 0.5 8 0.06–256
DRPM 0.5 8 0.06–32
GM 0.5 4 0.06–256
AMK 1 4 0.25–256
ABK 1 4 0.125–256
MINO 16 128 0.125–256
CPFX 0.25 4 0.06–128
LVFX 1 16 0.06–256
TFLX 0.25 32 0.06–32
GFLX 1 16 0.06–256
PZFX 0.5 8 0.06–256
TAZ/PIPC, TAZ ﬁ xed at 4 μg/ml and combined with various concentrations of PIPC
 289
With regard to S. aureus, the antimicrobial susceptibili-
ties of the strains were analyzed according to their classiﬁ ca-
tion as MSSA and MRSA. Approximately 73% of the 
MSSA strains were thought to be penicillinase-producing 
strains because of their resistance to ABPC and susceptibil-
ity to SBT/ABPC and CCL, and 15% of the MSSA strains 
were thought to be emr-harboring strains because of their 
resistance to macrolides (EM, CAM, and AZM), and sus-
ceptibility to TEL (a so-called ketolide lacking a sugar 
moiety to be recognized by the emr resistance mechanism).5 
The difference between the proportions of MSSA strains 
showing resistance to GM (13.3%) and to AMK (1.3%) 
implied the coexistence of aac(6′)/aph(2″)-harboring GM-
resistant strains with aad(4′, 4″)-harboring AMK-resistant 
strains.6
The incidence of MRSA was high, at 63.4%; this ﬁ nding 
is similar to the data reported by Mochizuki et al.,7 accord-
ing to analyses via WHONET 5. We found that the MRSA 
strains were susceptible to ABK, VCM, TEIC, and LZD, 
although a few strains were somewhat less susceptible to 
ABK (MIC 8.0 μg/ml); these strains may possess both aph 
(3′)-III and aa c(6′)/aph(2″) genes, as reported recently.6 
Although the emergence of MRSA strains resistant 
to VCM,8,9 TEIC, or LZD has already been reported in 
Japan, such a resistant strain was not detected in our 
surveillance.
Regarding S. pneumoniae, we found the proportions of 
PSSP/PISP/PRSP to be 61: 35: 4. Among PSSP, more than 
60% were thought to be emr-harboring strains because of 
their resistance to macrolides (EM, CAM, and AZM) and 
CLDM and their susceptibility to the ketolide TEL. As for 
PISP strains, their incidence (35%) in this survey of adult 
RTI was much lower than that (50.8%) reported in pediat-
ric infections.10–12 In general, we found that the antibacterial 
susceptibility of PISP was somewhat lower than that of 
PSSP: the activities of the penicillins (including those com-
bined with β-lactamase inhibitors) against PISP were 8 to 
32 times less than those against PSSP. Among the cephems, 
CCL, CFDN, CEZ, CTM, and CMZ showed 8 to 16 times 
less activity against PISP than against PSSP, while CDTR, 
CAZ, CTRX, CFPM, and CZOP showed 2 to 4 times less 
activity against PISP than against PSSP. The activities of 
the carbapenems, except for PAPM, against PISP were 4 
times less than those against PSSP. The activities of CFPN, 
PAPM, the ﬂ uoroquinolones, the glycopeptides, and LZD 
against PISP were the same as those against PSSP.
In this surveillance of pathogens in adult RTI, the inci-
dence of PRSP was very low (4.0%) as compared with that 
(16.9%–49.0%) reported in pediatric infections.10–12 This 
difference is thought to be attributable to the excessive use 
of oral penicillins and cephems in the pediatric population, 
because ﬂ uoroquinolones (except for norﬂ oxacin) are con-
traindicated in children. The pattern of antimicrobial sus-
ceptibility of PRSP somewhat resembled that of PISP; 
however, the PRSP strains were substantially susceptible 
(MIC90s ≤0.5 μg/ml) only to IPM, PAPM, TFLX, GFLX, 
TEL, VCM, and TEIC.
Concerning H. inﬂ uenzae, half of the strains showed 
decreased susceptibility to ABPC without the production 
of β-lactamase; i.e., 21.2% of the 165 H. inﬂ uenzae strains 
were BLNAI and 29.1% were BLNAR. The incidence of 
BLNAI in adults is thought to be somewhat lower than that 
in children (30.4%).13
It is well known that ﬂ uoroquinolones are exceptionally 
active against H. inﬂ uenzae, and such a feature was also 
remarkable in this surveillance; namely, all ﬁ ve ﬂ uoroqui-
nolones demonstrated extremely strong activity (MIC90 
≤0.06 μg/ml) against H. inﬂ uenzae strains regardless of their 
susceptibility to ABPC. Among the rest of the agents tested, 
PIPC, CDTR, CTRX, MEPM, and MINO showed strong 
activities (MIC90s of 0.25–0.5 μg/ml) against BLNAI and 
BLNAR, and TAZ restored the activity of PIPC against 
BLPAR markedly (MIC90 decreased from ≥256 μg/ml to 
≤0.5 μg/ml).
By means of a recently established method, the Cica-
Beta Test 1 (Kanto Chemical), for the detection of ESBLs 
and MBLs, two strains of K. pneumoniae were identiﬁ ed as 
ESBL-producing and three strains of P. aeruginosa were 
identiﬁ ed as MBL-producing. Such a low incidence of 
ESBL- and MBL-producing strains could be attributable to 
the type of infection in our surveillance, which was limited 
to adult RTI; a higher incidence of these strains has been 
reported in clinical isolates from patients with urinary tract 
infections.14
To conclude, this report has given an overview of the ﬁ rst 
nationwide surveillance of bacterial respiratory pathogens 
in adults conducted by the JSC; detailed analyses according 
to several stratiﬁ cation categories will be published 
elsewhere.
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